Primary and secondary time-to-event outcomes for the comparison of atazanavir plus didanosine-EC and emtricitabine to efavirenz plus lamivudine-zidovudine using data collected through 22 May 2008.

aAlso known as relative risk. Estimated from Cox regression model stratified by both country and RNA stratum and including randomized treatment group as sole covariate.bp-Value calculated from stratified log-rank test between arms.cThe five most common causes of death were infection (six deaths), liver disease (three deaths), malignancy (two deaths), suicide (two deaths), and unknown cause (two deaths).dDisease progression diagnoses are in Table S2; grade 3 and 4 laboratory events in Table S3; and signs and symptoms in Table S4.eAll events meeting these criteria are reported; some participants met criteria for multiple endpoints.fConfirmed plasma HIV RNA≥1,000 copies/ml at study week 16 or later.gElevated bilirubin concentration not included.hChange in any component of initial randomized antiretroviral regimen.iThe following antiretroviral substitutions were prespecified and were not included in this endpoint: TDF for DDI, stavudine or TDF for ZDV, or nevirapine for EFV.jCD4+ lymphocytes